Document is current
Any future updates will be listed below
-
Authors
Mjaess, Georges
Quackels, Thierry
Fantoni, Jean-Christophe
Tricard, Thibault
Marcq, Gautier
Blanc, Jérémy
Barthelemy, Philippe
Carnot, Aurélien
Sideris, Spyridon
Awada, Ahmad
Chanza, Nieves Martinez
Peltier, Alexandre
Albisinni, Simone
Diamand, Romain
Roumeguère, Thierry
-
Funding
Funding for this research was provided by:
Merck
- License Information
-
More Information
Article History
Received: 26 November 2025
Accepted: 3 January 2026
First Online: 13 January 2026
Declarations
:
: Thierry Roumeguère: Speaker for Johnsson and Johnsson, Astellas, Recordati Gauthier Marcq: Speaker for a pharmaceutical company: _BMS, MSD, Janssen, Astellas, Merck Serono. Support from a pharmaceutical company for participation in a national or international congress: _Bouchara Recordati, BMS, MSD, Janssen, Ipsen, Astellas, Photocure. Consultant: _Janssen, BMS__Principal investigator of a pharmaceutical industry trial: _MSD, Janssen, Fidia, Steba Biotech_Jérémy Blanc: FNRS funded PhD student, medical advisory (institutional) from Merck, travel support for medical congresses from Ipsen, Recordati, Merck and AstraZeneca. AC: honoraria for educational events from Astellas. Nieves Martinez Chanza: research travel from Pfizer and Ipsen, consulting fees (institutional) from BMS, Bayer and Merck.
: The rest of the authors declare no conflict of interest.
: The study was approved by the Hôpital Universitaire de Bruxelles research ethics committee (number of ethics approval: CE2716 ). The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. All patients have signed a written informed consent.
